ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

03 6 2023 06:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

15 5 2023 15:05:01 提供 Nasdaq GlobeNewswire

Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

10 5 2023 06:30:01 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

09 5 2023 06:30:01 提供 Nasdaq GlobeNewswire

Zevra Announces Board of Directors and Leadership Changes

08 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

03 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy

17 4 2023 15:05:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy

04 4 2023 06:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors

30 3 2023 06:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative

17 3 2023 06:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders

15 3 2023 06:26:12 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

07 3 2023 06:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at 35th Annual Roth Conference

06 3 2023 06:30:00 提供 Nasdaq GlobeNewswire